Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Review

Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) in human cancer

Authors: Peng Chen, Amit Sharma, Hans Weiher, Ingo G.H. Schmidt-Wolf

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

A firm link between endoplasmic reticulum (ER) stress and tumors has been wildly reported. Endoplasmic reticulum oxidoreductase 1 alpha (ERO1α), an ER-resident thiol oxidoreductase, is confirmed to be highly upregulated in various cancer types and associated with a significantly worse prognosis. Of importance, under ER stress, the functional interplay of ERO1α/PDI axis plays a pivotal role to orchestrate proper protein folding and other key processes. Multiple lines of evidence propose ERO1α as an attractive potential target for cancer treatment. However, the unavailability of specific inhibitor for ERO1α, its molecular inter-relatedness with closely related paralog ERO1β and the tightly regulated processes with other members of flavoenzyme family of enzymes, raises several concerns about its clinical translation. Herein, we have provided a detailed description of ERO1α in human cancers and its vulnerability towards the aforementioned concerns. Besides, we have discussed a few key considerations that may improve our understanding about ERO1α in tumors.
Literature
1.
Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling. Cell Mol Life Sci. 2016;73(1):79–94.PubMedCrossRef
2.
3.
Satoh T, Ross CA, Villa A, Supattapone S, Pozzan T, Snyder SH, Meldolesi J. The inositol 1,4,5,-trisphosphate receptor in cerebellar Purkinje cells: quantitative immunogold labeling reveals concentration in an ER subcompartment. J Cell Biol. 1990;111(2):615–24.PubMedCrossRef
4.
Walton PD, Airey JA, Sutko JL, Beck CF, Mignery GA, Sudhof TC, Deerinck TJ, Ellisman MH. Ryanodine and inositol trisphosphate receptors coexist in avian cerebellar Purkinje neurons. J Cell Biol. 1991;113(5):1145–57.PubMedCrossRef
5.
6.
Rao B, Wang Q, Yao D, Xia Y, Li W, Xie Y, Li S, Cao M, Shen Y, Qin A, et al. The cryo-EM structure of the human ERAD retrotranslocation complex. Sci Adv. 2023;9(41):eadi5656.PubMedPubMedCentralCrossRef
7.
Jayaraj GG, Hipp MS, Hartl FU. Functional modules of the Proteostasis Network. Cold Spring Harb Perspect Biol 2020, 12(1).
8.
Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21(2):71–88.PubMedCrossRef
9.
10.
Chang TK, Lawrence DA, Lu M, Tan J, Harnoss JM, Marsters SA, Liu P, Sandoval W, Martin SE, Ashkenazi A. Coordination between two branches of the unfolded protein response determines apoptotic cell fate. Mol Cell. 2018;71(4):629–636e625.PubMedCrossRef
11.
Mohamed E, Cao Y, Rodriguez PC. Endoplasmic reticulum stress regulates tumor growth and anti-tumor immunity: a promising opportunity for cancer immunotherapy. Cancer Immunol Immunother. 2017;66(8):1069–78.PubMedPubMedCentralCrossRef
12.
Lam M, Marsters SA, Ashkenazi A, Walter P. Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress. Elife 2020, 9.
13.
Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS, Paton AW, Paton JC, Walter P, Ashkenazi A. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science. 2014;345(6192):98–101.ADSPubMedPubMedCentralCrossRef
14.
McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol. 2001;21(4):1249–59.PubMedPubMedCentralCrossRef
15.
Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129(7):1337–49.PubMedCrossRef
16.
Galehdar Z, Swan P, Fuerth B, Callaghan SM, Park DS, Cregan SP. Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. J Neurosci. 2010;30(50):16938–48.PubMedPubMedCentralCrossRef
17.
Han D, Lerner AG, Vande Walle L, Upton JP, Xu W, Hagen A, Backes BJ, Oakes SA, Papa FR. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell. 2009;138(3):562–75.PubMedPubMedCentralCrossRef
18.
Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 2000;287(5453):664–6.ADSPubMedCrossRef
19.
Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014;14(9):581–97.PubMedCrossRef
20.
Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in Cancer. Cell. 2017;168(4):692–706.PubMedPubMedCentralCrossRef
21.
Urra H, Dufey E, Avril T, Chevet E, Hetz C. Endoplasmic reticulum stress and the hallmarks of Cancer. Trends Cancer. 2016;2(5):252–62.PubMedCrossRef
22.
Liang D, Khoonkari M, Avril T, Chevet E, Kruyt FAE. The unfolded protein response as regulator of cancer stemness and differentiation: mechanisms and implications for cancer therapy. Biochem Pharmacol. 2021;192:114737.PubMedCrossRef
23.
Calvo V, Zheng W, Adam-Artigues A, Staschke KA, Huang X, Cheung JF, Nobre AR, Fujisawa S, Liu D, Fumagalli M, et al. A PERK-Specific inhibitor blocks metastatic progression by limiting Integrated stress response-dependent survival of quiescent Cancer cells. Clin Cancer Res. 2023;29(24):5155–72.PubMedCrossRef
24.
Ranganathan AC, Adam AP, Zhang L, Aguirre-Ghiso JA. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther. 2006;5(7):729–35.PubMedCrossRef
25.
Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006;66(3):1702–11.PubMedPubMedCentralCrossRef
26.
Marciniak SJ, Chambers JE, Ron D. Pharmacological targeting of endoplasmic reticulum stress in disease. Nat Rev Drug Discov. 2022;21(2):115–40.PubMedCrossRef
27.
Salvagno C, Mandula JK, Rodriguez PC, Cubillos-Ruiz JR. Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. Trends Cancer. 2022;8(11):930–43.PubMedPubMedCentralCrossRef
28.
Ugalde JM, Aller I, Kudrjasova L, Schmidt RR, Schlosser M, Homagk M, Fuchs P, Lichtenauer S, Schwarzlander M, Muller-Schussele SJ, et al. Endoplasmic reticulum oxidoreductin provides resilience against reductive stress and hypoxic conditions by mediating luminal redox dynamics. Plant Cell. 2022;34(10):4007–27.PubMedPubMedCentralCrossRef
29.
Kojer K, Riemer J. Balancing oxidative protein folding: the influences of reducing pathways on disulfide bond formation. Biochim Biophys Acta. 2014;1844(8):1383–90.PubMedCrossRef
30.
Wang L, Wang CC. Oxidative protein folding fidelity and redoxtasis in the endoplasmic reticulum. Trends Biochem Sci. 2023;48(1):40–52.PubMedCrossRef
31.
Zhang J, Zhu Q, Wang X, Yu J, Chen X, Wang J, Wang X, Xiao J, Wang CC, Wang L. Secretory kinase Fam20C tunes endoplasmic reticulum redox state via phosphorylation of Ero1alpha. EMBO J 2018, 37(14).
32.
Inaba K, Masui S, Iida H, Vavassori S, Sitia R, Suzuki M. Crystal structures of human Ero1alpha reveal the mechanisms of regulated and targeted oxidation of PDI. EMBO J. 2010;29(19):3330–43.PubMedPubMedCentralCrossRef
33.
Shergalis AG, Hu S, Bankhead A 3rd, Neamati N. Role of the ERO1-PDI interaction in oxidative protein folding and disease. Pharmacol Ther. 2020;210:107525.PubMedPubMedCentralCrossRef
34.
Cabibbo A, Pagani M, Fabbri M, Rocchi M, Farmery MR, Bulleid NJ, Sitia R. ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum. J Biol Chem. 2000;275(7):4827–33.PubMedCrossRef
35.
Pagani M, Fabbri M, Benedetti C, Fassio A, Pilati S, Bulleid NJ, Cabibbo A, Sitia R. Endoplasmic reticulum oxidoreductin 1-lbeta (ERO1-Lbeta), a human gene induced in the course of the unfolded protein response. J Biol Chem. 2000;275(31):23685–92.PubMedCrossRef
36.
Dias-Gunasekara S, Gubbens J, van Lith M, Dunne C, Williams JA, Kataky R, Scoones D, Lapthorn A, Bulleid NJ, Benham AM. Tissue-specific expression and dimerization of the endoplasmic reticulum oxidoreductase Ero1beta. J Biol Chem. 2005;280(38):33066–75.PubMedCrossRef
37.
Li G, Mongillo M, Chin KT, Harding H, Ron D, Marks AR, Tabas I. Role of ERO1-alpha-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis. J Cell Biol. 2009;186(6):783–92.PubMedPubMedCentralCrossRef
38.
Spina A, Guidarelli A, Fiorani M, Varone E, Catalani A, Zito E, Cantoni O. Crosstalk between ERO1alpha and ryanodine receptor in arsenite-dependent mitochondrial ROS formation. Biochem Pharmacol. 2022;198:114973.PubMedCrossRef
39.
Bassot A, Chen J, Takahashi-Yamashiro K, Yap MC, Gibhardt CS, Le GNT, Hario S, Nasu Y, Moore J, Gutierrez T, et al. The endoplasmic reticulum kinase PERK interacts with the oxidoreductase ERO1 to metabolically adapt mitochondria. Cell Rep. 2023;42(1):111899.PubMedCrossRef
40.
Li G, Scull C, Ozcan L, Tabas I. NADPH oxidase links endoplasmic reticulum stress, oxidative stress, and PKR activation to induce apoptosis. J Cell Biol. 2010;191(6):1113–25.PubMedPubMedCentralCrossRef
41.
Zito E, Hansen HG, Yeo GS, Fujii J, Ron D. Endoplasmic reticulum thiol oxidase deficiency leads to ascorbic acid depletion and noncanonical scurvy in mice. Mol Cell. 2012;48(1):39–51.PubMedPubMedCentralCrossRef
42.
Zito E. PRDX4, an endoplasmic reticulum-localized peroxiredoxin at the crossroads between enzymatic oxidative protein folding and nonenzymatic protein oxidation. Antioxid Redox Signal. 2013;18(13):1666–74.PubMedCrossRef
43.
Nguyen VD, Saaranen MJ, Karala AR, Lappi AK, Wang L, Raykhel IB, Alanen HI, Salo KE, Wang CC, Ruddock LW. Two endoplasmic reticulum PDI peroxidases increase the efficiency of the use of peroxide during disulfide bond formation. J Mol Biol. 2011;406(3):503–15.PubMedCrossRef
44.
Kanemura S, Sofia EF, Hirai N, Okumura M, Kadokura H, Inaba K. Characterization of the endoplasmic reticulum-resident peroxidases GPx7 and GPx8 shows the higher oxidative activity of GPx7 and its linkage to oxidative protein folding. J Biol Chem. 2020;295(36):12772–85.PubMedPubMedCentralCrossRef
45.
Bulleid NJ. Disulfide bond formation in the mammalian endoplasmic reticulum. Cold Spring Harb Perspect Biol 2012, 4(11).
46.
Araki K, Inaba K. Structure, mechanism, and evolution of Ero1 family enzymes. Antioxid Redox Signal. 2012;16(8):790–9.PubMedCrossRef
47.
Matsusaki M, Okuda A, Matsuo K, Gekko K, Masuda T, Naruo Y, Hirose A, Kono K, Tsuchi Y, Urade R. Regulation of plant ER oxidoreductin 1 (ERO1) activity for efficient oxidative protein folding. J Biol Chem. 2019;294(49):18820–35.PubMedPubMedCentralCrossRef
48.
Masui S, Vavassori S, Fagioli C, Sitia R, Inaba K. Molecular bases of cyclic and specific disulfide interchange between human ERO1alpha protein and protein-disulfide isomerase (PDI). J Biol Chem. 2011;286(18):16261–71.PubMedPubMedCentralCrossRef
49.
Serve O, Kamiya Y, Maeno A, Nakano M, Murakami C, Sasakawa H, Yamaguchi Y, Harada T, Kurimoto E, Yagi-Utsumi M, et al. Redox-dependent domain rearrangement of protein disulfide isomerase coupled with exposure of its substrate-binding hydrophobic surface. J Mol Biol. 2010;396(2):361–74.PubMedCrossRef
50.
Nakasako M, Maeno A, Kurimoto E, Harada T, Yamaguchi Y, Oka T, Takayama Y, Iwata A, Kato K. Redox-dependent domain rearrangement of protein disulfide isomerase from a thermophilic fungus. Biochemistry. 2010;49(32):6953–62.PubMedCrossRef
51.
52.
Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal. 2007;9(12):2277–93.PubMedCrossRef
53.
Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931–47.PubMedCrossRef
54.
Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol. 2002;3(12):1129–34.PubMedCrossRef
55.
Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.PubMedPubMedCentralCrossRef
56.
Levitin F, Lee SCS, Hulme S, Rumantir RA, Wong AS, Meester MR, Koritzinsky M. Oxygen-independent disulfide bond formation in VEGF-A and CA9. J Biol Chem. 2021;296:100505.PubMedPubMedCentralCrossRef
57.
Koritzinsky M, Levitin F, van den Beucken T, Rumantir RA, Harding NJ, Chu KC, Boutros PC, Braakman I, Wouters BG. Two phases of disulfide bond formation have differing requirements for oxygen. J Cell Biol. 2013;203(4):615–27.PubMedPubMedCentralCrossRef
58.
Yang S, Yang C, Yu F, Ding W, Hu Y, Cheng F, Zhang F, Guan B, Wang X, Lu L, et al. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway. Cell Death Dis. 2018;9(11):1105.PubMedPubMedCentralCrossRef
59.
Tanaka T, Kutomi G, Kajiwara T, Kukita K, Kochin V, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Okamoto Y, et al. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer. Oncotarget. 2017;8(15):24706–18.PubMedPubMedCentralCrossRef
60.
Zito E, Melo EP, Yang Y, Wahlander A, Neubert TA, Ron D. Oxidative protein folding by an endoplasmic reticulum-localized peroxiredoxin. Mol Cell. 2010;40(5):787–97.PubMedPubMedCentralCrossRef
61.
Zito E, Chin KT, Blais J, Harding HP, Ron D. ERO1-beta, a pancreas-specific disulfide oxidase, promotes insulin biogenesis and glucose homeostasis. J Cell Biol. 2010;188(6):821–32.PubMedPubMedCentralCrossRef
62.
Yan W, Wang X, Liu T, Chen L, Han L, Xu J, Jin G, Harada K, Lin Z, Ren X. Expression of endoplasmic reticulum oxidoreductase 1-alpha in cholangiocarcinoma tissues and its effects on the proliferation and migration of cholangiocarcinoma cells. Cancer Manag Res. 2019;11:6727–39.PubMedPubMedCentralCrossRef
63.
Zhang Y, Li T, Zhang L, Shangguan F, Shi G, Wu X, Cui Y, Wang X, Wang X, Liu Y, et al. Targeting the functional interplay between endoplasmic reticulum oxidoreductin-1α and protein disulfide isomerase suppresses the progression of cervical cancer. EBioMedicine. 2019;41:408–19.PubMedPubMedCentralCrossRef
64.
Liu L, Wang C, Li S, Qu Y, Xue P, Ma Z, Zhang X, Bai H, Wang J. ERO1L is a novel and potential biomarker in lung adenocarcinoma and shapes the Immune-suppressive Tumor Microenvironment. Front Immunol. 2021;12:677169.PubMedPubMedCentralCrossRef
65.
Lei Y, Zang R, Lu Z, Zhang G, Huang J, Liu C, Wang Z, Mao S, Che Y, Wang X, et al. ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells. Cell Death Dis. 2020;11(10):853.PubMedPubMedCentralCrossRef
66.
Xie J, Liao G, Feng Z, Liu B, Li X, Qiu M. ERO1L promotes the proliferation and metastasis of lung adenocarcinoma via the Wnt2/β-catenin signaling pathway. Mol Carcinog. 2022;61(10):897–909.PubMedCrossRef
67.
Shi X, Wu J, Liu Y, Jiang Y, Zhi C, Li J. ERO1L promotes NSCLC development by modulating cell cycle-related molecules. Cell Biol Int. 2020;44(12):2473–84.PubMedPubMedCentralCrossRef
68.
Zhang J, Yang J, Lin C, Liu W, Huo Y, Yang M, Jiang SH, Sun Y, Hua R. Endoplasmic reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in pancreatic Cancer. Theranostics. 2020;10(18):8400–14.PubMedPubMedCentralCrossRef
69.
Han F, Xu Q, Zhao J, Xiong P, Liu J. ERO1L promotes pancreatic cancer cell progression through activating the Wnt/catenin pathway. J Cell Biochem. 2018;119(11):8996–9005.PubMedCrossRef
70.
Tanaka T, Kajiwara T, Torigoe T, Okamoto Y, Sato N, Tamura Y. Cancer-associated oxidoreductase ERO1-α drives the production of tumor-promoting myeloid-derived suppressor cells via oxidative protein folding. J Immunol. 2015;194(4):2004–10.PubMedCrossRef
71.
Cornelius J, Cavarretta I, Pozzi E, Lavorgna G, Locatelli I, Tempio T, Montorsi F, Mattei A, Sitia R, Salonia A, et al. Endoplasmic reticulum oxidoreductase 1 alpha modulates prostate cancer hallmarks. Transl Androl Urol. 2021;10(3):1110–20.PubMedPubMedCentralCrossRef
72.
Zhou B, Wang G, Gao S, Chen Y, Jin C, Wang Z, Yang Y, Ma Z, Zhang W, Feng X. Expression of ERO1L in gastric cancer and its association with patient prognosis. Exp Ther Med. 2017;14(3):2298–302.PubMedPubMedCentralCrossRef
73.
Chambers JE, Tavender TJ, Oka OB, Warwood S, Knight D, Bulleid NJ. The reduction potential of the active site disulfides of human protein disulfide isomerase limits oxidation of the enzyme by Ero1alpha. J Biol Chem. 2010;285(38):29200–7.PubMedPubMedCentralCrossRef
74.
75.
Appenzeller-Herzog C, Riemer J, Christensen B, Sorensen ES, Ellgaard L. A novel disulphide switch mechanism in Ero1alpha balances ER oxidation in human cells. EMBO J. 2008;27(22):2977–87.PubMedPubMedCentralCrossRef
76.
Baker KM, Chakravarthi S, Langton KP, Sheppard AM, Lu H, Bulleid NJ. Low reduction potential of Ero1alpha regulatory disulphides ensures tight control of substrate oxidation. EMBO J. 2008;27(22):2988–97.PubMedPubMedCentralCrossRef
77.
Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP, Ron D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004;18(24):3066–77.PubMedPubMedCentralCrossRef
78.
Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest. 2008;118(10):3378–89.PubMedPubMedCentralCrossRef
79.
Akman M, Belisario DC, Salaroglio IC, Kopecka J, Donadelli M, De Smaele E, Riganti C. Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. J Exp Clin Cancer Res. 2021;40(1):28.PubMedPubMedCentralCrossRef
80.
Bartoszewska S, Collawn JF, Bartoszewski R. The Role of the Hypoxia-Related Unfolded Protein Response (UPR) in the Tumor Microenvironment. Cancers (Basel) 2022, 14(19).
81.
Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res. 2009;37(14):4587–602.PubMedPubMedCentralCrossRef
82.
May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E. Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene. 2005;24(6):1011–20.PubMedCrossRef
83.
Battle DM, Gunasekara SD, Watson GR, Ahmed EM, Saysell CG, Altaf N, Sanusi AL, Munipalle PC, Scoones D, Walker J, et al. Expression of the endoplasmic reticulum oxidoreductase Ero1alpha in gastro-intestinal cancer reveals a link between homocysteine and oxidative protein folding. Antioxid Redox Signal. 2013;19(1):24–35.PubMedCrossRef
84.
Moon HG, Hwang KT, Kim JA, Kim HS, Lee MJ, Jung EM, Ko E, Han W, Noh DY. NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol. 2011;5(6):538–44.PubMedPubMedCentralCrossRef
85.
Denny SK, Yang D, Chuang CH, Brady JJ, Lim JS, Gruner BM, Chiou SH, Schep AN, Baral J, Hamard C, et al. Nfib Promotes Metastasis through a widespread increase in chromatin accessibility. Cell. 2016;166(2):328–42.PubMedPubMedCentralCrossRef
86.
Chang CY, Pasolli HA, Giannopoulou EG, Guasch G, Gronostajski RM, Elemento O, Fuchs E. NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche. Nature. 2013;495(7439):98–102.ADSPubMedPubMedCentralCrossRef
87.
Zilli F, Marques Ramos P, Auf der Maur P, Jehanno C, Sethi A, Coissieux MM, Eichlisberger T, Sauteur L, Rouchon A, Bonapace L, et al. The NFIB-ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells. EMBO Mol Med. 2021;13(4):e13162.PubMedPubMedCentralCrossRef
88.
Li X, Li Y, Jiang C, Chen L, Gan N. MicroRNA-144-3p inhibits tumorigenesis of oral squamous cell carcinoma by downregulating ERO1L. J Cancer. 2020;11(3):759–68.PubMedPubMedCentralCrossRef
89.
Huang D, Li C. circ-ACACA promotes proliferation, invasion, migration and glycolysis of cervical cancer cells by targeting the miR-582-5p/ERO1A signaling axis. Oncol Lett. 2021;22(5):795.PubMedPubMedCentralCrossRef
90.
Chen G, Wang Q, Wang K. MicroRNA-218-5p affects lung adenocarcinoma progression through targeting endoplasmic reticulum oxidoreductase 1 alpha. Bioengineered. 2022;13(4):10061–70.PubMedPubMedCentralCrossRef
91.
92.
Shen J, Jiao Y, Ding N, Xie L, Ma S, Zhang H, Yang A, Zhang H, Jiang Y. Homocysteine facilitates endoplasmic reticulum stress and apoptosis of hepatocytes by suppressing ERO1alpha expression via cooperation between DNMT1 and G9a. Cell Biol Int. 2022;46(8):1236–48.PubMedPubMedCentralCrossRef
93.
Lee S, Lee E, Ko E, Ham M, Lee HM, Kim ES, Koh M, Lim HK, Jung J, Park SY, et al. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. Cancer Lett. 2018;437:25–34.PubMedCrossRef
94.
Tanaka T, Kutomi G, Kajiwara T, Kukita K, Kochin V, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Okamoto Y, et al. Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level. Br J Cancer. 2016;114(11):1227–34.PubMedPubMedCentralCrossRef
95.
Kutomi G, Tamura Y, Tanaka T, Kajiwara T, Kukita K, Ohmura T, Shima H, Takamaru T, Satomi F, Suzuki Y, et al. Human endoplasmic reticulum oxidoreductin 1-α is a novel predictor for poor prognosis of breast cancer. Cancer Sci. 2013;104(8):1091–6.PubMedPubMedCentralCrossRef
96.
Varone E, Decio A, Chernorudskiy A, Minoli L, Brunelli L, Ioli F, Piotti A, Pastorelli R, Fratelli M, Gobbi M, et al. The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions. Oncogene. 2021;40(9):1721–36.PubMedPubMedCentralCrossRef
97.
Liu L, Li S, Qu Y, Wang J, Fei K, Wang C, Zhang X, Ma Z, Bai H, Wang J. Tumour ERO1A instigates T cell dysfunction by transmission of endoplasmic reticulum stress. J Clin Oncol. 2022;40(16suppl):e14533–3.CrossRef
98.
Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS, Yu CJ. Identification and characterization of potential biomarkers by Quantitative Tissue Proteomics of Primary Lung Adenocarcinoma. Mol Cell Proteom. 2016;15(7):2396–410.CrossRef
99.
Yang J, Xu Y, Huo Y, Cai L, Hua R, Zhang J, Chen Z. ERO1L Promotes Hepatic Metastasis through Activating Epithelial-Mesenchymal Transition (EMT) in Pancreatic Cancer. J Immunol Res 2021, 2021:5553425.
100.
Seol SY, Kim C, Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH, Cho JY. Overexpression of endoplasmic reticulum oxidoreductin 1-α (ERO1L) is Associated with poor prognosis of gastric Cancer. Cancer Res Treat. 2016;48(4):1196–209.PubMedPubMedCentralCrossRef
101.
Takei N, Yoneda A, Sakai-Sawada K, Kosaka M, Minomi K, Tamura Y. Hypoxia-inducible ERO1α promotes cancer progression through modulation of integrin-β1 modification and signalling in HCT116 colorectal cancer cells. Sci Rep. 2017;7(1):9389.ADSPubMedPubMedCentralCrossRef
102.
Barcellos-Hoff MH, Lyden D, Wang TC. The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer. 2013;13(7):511–8.PubMedCrossRef
103.
104.
Li Y, Yang J, Dai C, Wu C, Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest. 2003;112(4):503–16.PubMedPubMedCentralCrossRef
105.
106.
Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 2003;93(11):1074–81.PubMedCrossRef
107.
108.
Waypa GB, Marks JD, Guzy R, Mungai PT, Schriewer J, Dokic D, Schumacker PT. Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells. Circ Res. 2010;106(3):526–35.PubMedCrossRef
109.
Varone E, Chernorudskiy A, Cherubini A, Cattaneo A, Bachi A, Fumagalli S, Erol G, Gobbi M, Lenardo MJ, Borgese N, et al. ERO1 alpha deficiency impairs angiogenesis by increasing N-glycosylation of a proangiogenic VEGFA. Redox Biol. 2022;56:102455.PubMedPubMedCentralCrossRef
110.
Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92.PubMedCrossRef
111.
Liu L, Li S, Qu Y, Bai H, Pan X, Wang J, Wang Z, Duan J, Zhong J, Wan R et al. Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. Cell Rep Med 2023:101206.
112.
Tay A, Lundqvist A, Sze SK. Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma. Cancer Res. 2023;83(7Supplement):4466–6.CrossRef
113.
Lu C, Liu Y, Ali NM, Zhang B, Cui X. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol. 2022;13:1039260.PubMedCrossRef
114.
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.PubMedPubMedCentralCrossRef
115.
Belgiovine C, D’Incalci M, Allavena P, Frapolli R. Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci. 2016;73(13):2411–24.PubMedCrossRef
116.
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96.PubMedCrossRef
117.
Hurst KE, Lawrence KA, Essman MT, Walton ZJ, Leddy LR, Thaxton JE. Endoplasmic reticulum stress contributes to mitochondrial exhaustion of CD8(+) T cells. Cancer Immunol Res. 2019;7(3):476–86.PubMedPubMedCentralCrossRef
118.
Reczek CR, Chandel NS. The two faces of reactive oxygen species in cancer. Annual Rev cancer Biology. 2017;1:79–98.CrossRef
119.
Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579–91.PubMedCrossRef
120.
121.
122.
Varone E, Decio A, Barbera MC, Bolis M, Di Rito L, Pisati F, Giavazzi R, Zito E. Endoplasmic reticulum oxidoreductin 1-alpha deficiency and activation of protein translation synergistically impair breast tumour resilience. Br J Pharmacol. 2022;179(23):5180–95.PubMedCrossRef
123.
Yadunandam AK, Yoon JS, Seong YA, Oh CW, Kim GD. Prospective impact of 5-FU in the induction of endoplasmic reticulum stress, modulation of GRP78 expression and autophagy in Sk-Hep1 cells. Int J Oncol. 2012;41(3):1036–42.PubMedCrossRef
124.
Liao PC, Tan SK, Lieu CH, Jung HK. Involvement of endoplasmic reticulum in paclitaxel-induced apoptosis. J Cell Biochem. 2008;104(4):1509–23.PubMedCrossRef
125.
Wang G, Han J, Wang G, Wu X, Huang Y, Wu M, Chen Y. ERO1α mediates endoplasmic reticulum stress-induced apoptosis via microRNA-101/EZH2 axis in colon cancer RKO and HT-29 cells. Hum Cell. 2021;34(3):932–44.PubMedCrossRef
126.
Liu Z, Zhang K, Zhao Z, Qin Z, Tang H. Prognosis-related autophagy genes in female lung adenocarcinoma. Med (Baltim). 2022;101(1):e28500.CrossRef
127.
Guo Q, Liu XL, Liu HS, Luo XY, Yuan Y, Ji YM, Liu T, Guo JL, Zhang J. The Risk Model Based on the Three Oxidative Stress-Related Genes Evaluates the Prognosis of LAC Patients. Oxid Med Cell Longev 2022, 2022:4022896.
128.
Zhu J, Wang M, Hu D. Development of an autophagy-related gene prognostic signature in lung adenocarcinoma and lung squamous cell carcinoma. PeerJ. 2020;8:e8288.PubMedPubMedCentralCrossRef
129.
Nie H, Luo C, Liao K, Xu J, Cheng XX, Wang X. Seven glycolysis-related genes predict the prognosis of patients with pancreatic Cancer. Front Cell Dev Biol. 2021;9:647106.PubMedPubMedCentralCrossRef
130.
131.
Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–24.PubMedCrossRef
132.
Hayes KE, Batsomboon P, Chen WC, Johnson BD, Becker A, Eschrich S, Yang Y, Robart AR, Dudley GB, Geldenhuys WJ, et al. Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma. Bioorg Med Chem. 2019;27(8):1479–88.PubMedPubMedCentralCrossRef
133.
Blais JD, Chin KT, Zito E, Zhang Y, Heldman N, Harding HP, Fass D, Thorpe C, Ron D. A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity. J Biol Chem. 2010;285(27):20993–1003.PubMedPubMedCentralCrossRef
134.
Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, et al. The genetic landscape of a cell. Science. 2010;327(5964):425–31.ADSPubMedPubMedCentralCrossRef
135.
Johnson BD, Kaulagari S, Chen WC, Hayes K, Geldenhuys WJ, Hazlehurst LA. Identification of natural product sulfuretin derivatives as inhibitors for the endoplasmic reticulum redox protein ERO1alpha. ACS Bio Med Chem Au. 2022;2(2):161–70.PubMedPubMedCentralCrossRef
136.
Rahman NSA, Zahari S, Syafruddin SE, Firdaus-Raih M, Low TY, Mohtar MA. Functions and mechanisms of protein disulfide isomerase family in cancer emergence. Cell Biosci. 2022;12(1):129.PubMedPubMedCentralCrossRef
137.
138.
139.
140.
Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001;98(15):8554–9.ADSPubMedPubMedCentralCrossRef
141.
Zeng S, Huang W, Zheng X, Liyan C, Zhang Z, Wang J, Shen Z. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges. Eur J Med Chem. 2021;210:112981.PubMedCrossRef
142.
Wu J, Chen S, Liu H, Zhang Z, Ni Z, Chen J, Yang Z, Nie Y, Fan D. Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation. J Exp Clin Cancer Res. 2018;37(1):272.PubMedPubMedCentralCrossRef
143.
144.
Sharma A, Schmidt-Wolf IGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res. 2021;40(1):388.PubMedPubMedCentralCrossRef
145.
Wright J, Birk J, Haataja L, Liu M, Ramming T, Weiss MA, Appenzeller-Herzog C, Arvan P. Endoplasmic reticulum oxidoreductin-1alpha (Ero1alpha) improves folding and secretion of mutant proinsulin and limits mutant proinsulin-induced endoplasmic reticulum stress. J Biol Chem. 2013;288(43):31010–8.PubMedPubMedCentralCrossRef
146.
Nardai G, Stadler K, Papp E, Korcsmaros T, Jakus J, Csermely P. Diabetic changes in the redox status of the microsomal protein folding machinery. Biochem Biophys Res Commun. 2005;334(3):787–95.PubMedCrossRef
147.
Lehtonen S, Jaronen M, Vehvilainen P, Lakso M, Rudgalvyte M, Keksa-Goldsteine V, Wong G, Courtney MJ, Koistinaho J, Goldsteins G. Inhibition of excessive oxidative protein folding is protective in MPP(+) toxicity-Induced Parkinson’s Disease models. Antioxid Redox Signal. 2016;25(8):485–97.PubMedCrossRef
148.
149.
Wang K, Liu JQ, Zhong T, Liu XL, Zeng Y, Qiao X, Xie T, Chen Y, Gao YY, Tang B, et al. Phase separation and cytotoxicity of tau are modulated by protein disulfide isomerase and S-nitrosylation of this molecular chaperone. J Mol Biol. 2020;432(7):2141–63.PubMedCrossRef
150.
Zhou X, Li G, Kaplan A, Gaschler MM, Zhang X, Hou Z, Jiang M, Zott R, Cremers S, Stockwell BR, et al. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington’s disease. Hum Mol Genet. 2018;27(9):1545–55.PubMedPubMedCentralCrossRef
151.
Parakh S, Shadfar S, Perri ER, Ragagnin AMG, Piattoni CV, Fogolin MB, Yuan KC, Shahheydari H, Don EK, Thomas CJ et al. The Redox activity of protein disulfide isomerase inhibits ALS phenotypes in Cellular and zebrafish models. iScience 2020, 23(5):101097.
152.
Woehlbier U, Colombo A, Saaranen MJ, Perez V, Ojeda J, Bustos FJ, Andreu CI, Torres M, Valenzuela V, Medinas DB, et al. ALS-linked protein disulfide isomerase variants cause motor dysfunction. EMBO J. 2016;35(8):845–65.PubMedPubMedCentralCrossRef
153.
Chin KT, Kang G, Qu J, Gardner LB, Coetzee WA, Zito E, Fishman GI, Ron D. The sarcoplasmic reticulum luminal thiol oxidase ERO1 regulates cardiomyocyte excitation-coupled calcium release and response to hemodynamic load. FASEB J. 2011;25(8):2583–91.PubMedPubMedCentralCrossRef
154.
Yang X, Xu H, Hao Y, Zhao L, Cai X, Tian J, Zhang M, Han X, Ma S, Cao J, et al. Endoplasmic reticulum oxidoreductin 1alpha mediates hepatic endoplasmic reticulum stress in homocysteine-induced atherosclerosis. Acta Biochim Biophys Sin (Shanghai). 2014;46(10):902–10.PubMedCrossRef
155.
Swiatkowska M, Padula G, Michalec L, Stasiak M, Skurzynski S, Cierniewski CS. Ero1alpha is expressed on blood platelets in association with protein-disulfide isomerase and contributes to redox-controlled remodeling of alphaIIbbeta3. J Biol Chem. 2010;285(39):29874–83.PubMedPubMedCentralCrossRef
Metadata
Title
Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) in human cancer
Authors
Peng Chen
Amit Sharma
Hans Weiher
Ingo G.H. Schmidt-Wolf
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-02990-4

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue

Research

The synergism of SMC1A cohesin gene silencing and bevacizumab against colorectal cancer

Research

TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO

Research

The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

Research

The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis

Research

Lactylation stabilizes DCBLD1 activating the pentose phosphate pathway to promote cervical cancer progression

Review

Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits